BACKGROUND: The incidence of non-Hodgkin lymphoma and prevalence of obesity are increasing globally. A suggested positive association between obesity and risk of non-Hodgkin lymphoma has prompted us to investigate the relationship between body mass index (BMI) and risk of malignant lymphoma subtypes in a population-based case-control study. METHODS: Telephone interviews were conducted with 3055 case patients with non-Hodgkin lymphoma and 618 case patients with Hodgkin lymphoma diagnosed between October 1, 1999, and August 30, 2002, and 3187 population-based control subjects. The interviews assessed current height, normal adult weight, and other possible risk factors. Multivariable odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for risk of lymphoma were estimated by unconditional logistic regression. All statistical tests were two-sided. RESULTS: BMI was not associated with risk of overall non-Hodgkin lymphoma or of Hodgkin lymphoma (for example, comparing the highly obese group [BMI > or =35.0 kg/m2] with the normal-weight group [BMI = 18.5-24.9 kg/m2], OR for risk of non-Hodgkin lymphoma = 0.9, 95% CI = 0.6 to 1.3; P(trend) across all categories of BMI = .27). BMI was also not associated with risk of any non-Hodgkin lymphoma subtype evaluated, although there was some evidence of a positive association with risk of diffuse large B-cell lymphoma (for example, comparing the highly obese group with the normal-weight group, OR for diffuse large B-cell lymphoma = 1.5, 95% CI = 0.9 to 2.4; P(trend) =.05). CONCLUSIONS: Excess weight does not appear to be associated with an increased risk of malignant lymphoma in general, or with a risk of most major lymphoma subtypes. Hence, the growing incidence of obesity is unlikely to be an important contributor to the increasing incidence of non-Hodgkin lymphoma worldwide.
BACKGROUND: The incidence of non-Hodgkin lymphoma and prevalence of obesity are increasing globally. A suggested positive association between obesity and risk of non-Hodgkin lymphoma has prompted us to investigate the relationship between body mass index (BMI) and risk of malignant lymphoma subtypes in a population-based case-control study. METHODS: Telephone interviews were conducted with 3055 case patients with non-Hodgkin lymphoma and 618 case patients with Hodgkin lymphoma diagnosed between October 1, 1999, and August 30, 2002, and 3187 population-based control subjects. The interviews assessed current height, normal adult weight, and other possible risk factors. Multivariable odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for risk of lymphoma were estimated by unconditional logistic regression. All statistical tests were two-sided. RESULTS: BMI was not associated with risk of overall non-Hodgkin lymphoma or of Hodgkin lymphoma (for example, comparing the highly obese group [BMI > or =35.0 kg/m2] with the normal-weight group [BMI = 18.5-24.9 kg/m2], OR for risk of non-Hodgkin lymphoma = 0.9, 95% CI = 0.6 to 1.3; P(trend) across all categories of BMI = .27). BMI was also not associated with risk of any non-Hodgkin lymphoma subtype evaluated, although there was some evidence of a positive association with risk of diffuse large B-cell lymphoma (for example, comparing the highly obese group with the normal-weight group, OR for diffuse large B-cell lymphoma = 1.5, 95% CI = 0.9 to 2.4; P(trend) =.05). CONCLUSIONS: Excess weight does not appear to be associated with an increased risk of malignant lymphoma in general, or with a risk of most major lymphoma subtypes. Hence, the growing incidence of obesity is unlikely to be an important contributor to the increasing incidence of non-Hodgkin lymphoma worldwide.
Authors: Geoffrey C Kabat; Mimi Y Kim; Jennifer W Bea; Kerstin L Edlefsen; Lucile L Adams-Campbell; Anneclaire J De Roos; Thomas E Rohan Journal: Cancer Epidemiol Date: 2011-08-04 Impact factor: 2.984
Authors: Yani Lu; Jennifer Prescott; Jane Sullivan-Halley; Katherine D Henderson; Huiyan Ma; Ellen T Chang; Christina A Clarke; Pamela L Horn-Ross; Giske Ursin; Leslie Bernstein Journal: Am J Epidemiol Date: 2009-10-12 Impact factor: 4.897
Authors: Jennifer L Kelly; Zachary S Fredericksen; Mark Liebow; Tait D Shanafelt; Carrie A Thompson; Timothy G Call; Thomas M Habermann; William R Macon; Alice H Wang; Susan L Slager; James R Cerhan Journal: Ann Epidemiol Date: 2012-11-10 Impact factor: 3.797
Authors: Eleanor Kane; Christine F Skibola; Paige M Bracci; James R Cerhan; Laura Costas; Karin Ekström Smedby; Elizabeth A Holly; Marc Maynadié; Anne J Novak; Tracy J Lightfoot; Stephen M Ansell; Alex G Smith; Mark Liebow; Mads Melbye; Lindsay Morton; Silvia de Sanjosé; Susan L Slager; Sophia S Wang; Yawei Zhang; Tongzhang Zheng; Eve Roman Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-11 Impact factor: 4.254
Authors: Eleanor V Willett; Lindsay M Morton; Patricia Hartge; Nikolaus Becker; Leslie Bernstein; Paolo Boffetta; Paige Bracci; James Cerhan; Brian C-H Chiu; Pierluigi Cocco; Luigino Dal Maso; Scott Davis; Silvia De Sanjose; Karin Ekstrom Smedby; Maria Grazia Ennas; Lenka Foretova; Elizabeth A Holly; Carlo La Vecchia; Keitaro Matsuo; Marc Maynadie; Mads Melbye; Eva Negri; Alexandra Nieters; Richard Severson; Susan L Slager; John J Spinelli; Anthony Staines; Renato Talamini; Martine Vornanen; Dennis D Weisenburger; Eve Roman Journal: Int J Cancer Date: 2008-05-01 Impact factor: 7.396
Authors: Qian Li; Ellen T Chang; Bryan A Bassig; Min Dai; Qin Qin; Yongshun Gao; Yawei Zhang; Tongzhang Zheng Journal: Cancer Causes Control Date: 2012-12-04 Impact factor: 2.506